These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 11590630)

  • 1. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes.
    Molenberghs G; Geys H; Buyse M
    Stat Med; 2001 Oct; 20(20):3023-38. PubMed ID: 11590630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An information-theoretic approach for the assessment of a continuous outcome as a surrogate for a binary true endpoint based on causal inference: Application to vaccine evaluation.
    Alonso Abad A; Ong F; Stijven F; Van der Elst W; Molenberghs G; Van Keilegom I; Verbeke G; Callegaro A
    Stat Med; 2024 Mar; 43(6):1083-1102. PubMed ID: 38164018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Time-to-event surrogate endpoint validation using mediation analysis and meta-analytic data.
    Le Coënt Q; Legrand C; Rondeau V
    Biostatistics; 2023 Dec; 25(1):98-116. PubMed ID: 36398615
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Surrogate endpoints: a key concept in clinical epidemiology.
    Christensen R; Ciani O; Manyara AM; Taylor RS
    J Clin Epidemiol; 2024 Mar; 167():111242. PubMed ID: 38142762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantifying proportion of treatment effect by surrogate endpoint under heterogeneity.
    Guo X; Bourgeois FT; Cai T
    Stat Methods Med Res; 2024 Jul; 33(7):1152-1162. PubMed ID: 38717356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Proportion of treatment effect explained: An overview of interpretations.
    Stijven F; Alonso A; Molenberghs G
    Stat Methods Med Res; 2024 Jul; 33(7):1278-1296. PubMed ID: 39053571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risky reliance on small surrogate endpoint studies when planning a large prevention trial.
    Baker SG; Kramer BS
    J R Stat Soc Ser A Stat Soc; 2013 Feb; 176(2):603-608. PubMed ID: 23565041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. On the individual surrogate paradox.
    Ma L; Yin Y; Liu L; Geng Z
    Biostatistics; 2021 Jan; 22(1):97-113. PubMed ID: 31215619
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Large simple trials: really, it can't be that simple!
    Califf RM
    Eur Heart J; 2014 Mar; 35(9):549-51. PubMed ID: 24408889
    [No Abstract]   [Full Text] [Related]  

  • 10. Discussion of "Missing Data Methods in Longitudinal Studies: A Review" by Ibrahim and Molenberghs.
    Daniels MJ; Wang C
    Test (Madr); 2009 May; 18(1):51-58. PubMed ID: 21949475
    [No Abstract]   [Full Text] [Related]  

  • 11. Informed decision-making: Statistical methodology for surrogacy evaluation and its role in licensing and reimbursement assessments.
    Weir CJ; Taylor RS
    Pharm Stat; 2022 Jul; 21(4):740-756. PubMed ID: 35819121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Longitudinal Joint Modelling of Ordinal and Overdispersed Count Outcomes: A Bridge Distribution for the Ordinal Random Intercept.
    Amini P; Moghimbeigi A; Zayeri F; Tapak L; Maroufizadeh S; Verbeke G
    Comput Math Methods Med; 2021; 2021():5521881. PubMed ID: 33763151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measuring Surrogacy in Clinical Research: With an application to studying surrogate markers for HIV Treatment-as-Prevention.
    Zhuang R; Chen YQ
    Stat Biosci; 2020 Dec; 12(3):295-323. PubMed ID: 33737982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of surrogacy in the multi-trial setting based on information theory: an extension to ordinal outcomes.
    Ensor H; Weir CJ
    J Biopharm Stat; 2020 Mar; 30(2):364-376. PubMed ID: 31887069
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A systematic literature review of evidence-based clinical practice for rare diseases: what are the perceived and real barriers for improving the evidence and how can they be overcome?
    Rath A; Salamon V; Peixoto S; Hivert V; Laville M; Segrestin B; Neugebauer EAM; Eikermann M; Bertele V; Garattini S; Wetterslev J; Banzi R; Jakobsen JC; Djurisic S; Kubiak C; Demotes-Mainard J; Gluud C
    Trials; 2017 Nov; 18(1):556. PubMed ID: 29166947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accounting for treatment by center interaction in sample size determinations and the use of surrogate outcomes in the pessary for the prevention of preterm birth trial: a simulation study.
    Willan AR
    Trials; 2016 Jul; 17(1):310. PubMed ID: 27378231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Creatinine Change on Vasoconstrictors as Mortality Surrogate in Hepatorenal Syndrome: Systematic Review & Meta-Analysis.
    Belcher JM; Coca SG; Parikh CR
    PLoS One; 2015; 10(8):e0135625. PubMed ID: 26295585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developing retinal biomarkers of neurological disease: an analytical perspective.
    MacCormick IJ; Czanner G; Faragher B
    Biomark Med; 2015; 9(7):691-701. PubMed ID: 26174843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The perils of surrogate endpoints.
    Weintraub WS; Lüscher TF; Pocock S
    Eur Heart J; 2015 Sep; 36(33):2212-8. PubMed ID: 25975658
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.